Research programme: neuropsychiatric disorder therapies - Eli Lilly/PsychoGenics

Drug Profile

Research programme: neuropsychiatric disorder therapies - Eli Lilly/PsychoGenics

Latest Information Update: 11 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; PsychoGenics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Neurological disorders; Psychiatric disorders

Most Recent Events

  • 01 Feb 2008 Eli Lilly and PsychoGenics enter into an additional drug discovery agreement for the treatment of neuropsychiatric disorders
  • 21 Dec 2006 Early research in Psychiatric disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top